Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- Registration Number
- NCT00005826
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have glioblastoma multiforme.
- Detailed Description
OBJECTIVES: I. Assess the therapeutic activity and toxicities of nitrocamptothecin in patients with glioblastoma multiforme. II. Determine the overall response, duration of response, and progression free survival of these patients after this treatment.
OUTLINE: This is a multicenter study. Patients receive nitrocamptothecin orally daily on days 1-5. Treatment continues every 7 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks until disease progression in the absence of further treatment.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (13)
Azienda Ospedaliera di Padova
🇮🇹Padua, Italy
Centre Eugene Marquis
🇫🇷Rennes, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Ospedale San Giovanni
🇨ðŸ‡Bellinzona, Switzerland
Centre Henri Becquerel
🇫🇷Rouen, France
Universitair Ziekenhuis Antwerpen
🇧🇪Edegem, Belgium
CRLCC Nantes - Atlantique
🇫🇷Nantes-Saint Herblain, France
Centre Jean Perrin
🇫🇷Clermont-Ferrand, France
Centre de Lute Contre le Cancer,Georges-Francois Leclerc
🇫🇷Dijon, France
Centre Leon Berard
🇫🇷Lyon, France
Clinique De Genolier
🇨ðŸ‡Genolier, Switzerland
Academisch Ziekenhuis der Vrije Universiteit
🇳🇱Amsterdam, Netherlands
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain